There is currently no approved treatment for intracerebral haemorrhage (ICH), the deadliest form of stroke. But Bioxodes, a Walloon start-up, believes the answer may lie in one of nature’s most unlikely places: the saliva of ticks. The company is developing a drug inspired by this natural compound and could become the first to commercialise a treatment for ICH, potentially changing the outlook for thousands of patients worldwide.